Pelade au cours d’un traitement par anti-TNF alpha : neuf cas

Bidre, Emmanuelle Le; Chaby, G.; Martin, Ludovic; Perrussel, M.; Sassolas, B.; Sigal, M.-L.; Kaassis, C.; Lespessailles, Éric; Nseir, A.; Estève, É.

doi:10.1016/j.annder.2011.01.047

Cited by 29 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from the commonly advocated adverse effects, there are certain other side effects which are either less known or are under reported. Occurrence of alopecia areata with TNF ⍺ antagonists (Etanercept) is such In our case the time elapsed after the introduction of the anti-TNF alpha agent Etanercept to the development of AA was 4.5 months which is similar to the case study by Le Bidre, et al [12]. Improvement in alopecia even without treatment on cessation of the Etanercept strongly high-lights the association between the two entities.…”

Section: Discussionsupporting

confidence: 75%

Biologic: A Double Edged Sword - A Case of Etanercept Induced Alopecia Areata in a Patient with Psoriasis Vulgaris

Chowdhry¹,

Priya²,

D’Souza³

et al. 2018

SOJMID

View full text Add to dashboard Cite

Psoriasis vulgaris is a chronic inflammatory disorder which can only be controlled with medications but not cured. Various modalities are available for the management of same with varying efficacy and adverse effects. Biologics, though not new, have changed the concept of treatment of psoriasis. With beneficial effects, they also have adverse effects which are being identified more and more with passing time.

show abstract

Section: Discussionsupporting

confidence: 75%

Biologic: A Double Edged Sword - A Case of Etanercept Induced Alopecia Areata in a Patient with Psoriasis Vulgaris

Chowdhry¹,

Priya²,

D’Souza³

et al. 2018

SOJMID

View full text Add to dashboard Cite

show abstract

“…As a result of the study, it was found as ineffective [79]. Several reports have been published indicating the development of AA during a treatment of anti-TNF-α for another disease [80][81][82][83][84][85][86]. Gorcey et al reported a patient with AU, refractory to various treatment modalities, who was successfully treated with adalimumab, while being treated for the flare of atopic dermatitis [87].…”

Section: Tumor Necrosis Factor (Tnf)-α Inhibitorsmentioning

confidence: 96%

New Modalities in the Treatment of Refractory Alopecia Areata

Kılıç¹

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

Alopecia areata (AA) is a common and complex T-cell-mediated inflammatory disorder. It may be patchy (localized), involve the entire scalp (alopecia totalis) or entire body (alopecia universalis). Alopecia totalis and universalis are often difficult to treat. Although many therapeutic options currently exist in alopecia areata, none of them are curative or preventive. Besides, none of them are approved by Food and Drug Administration (FDA). The disease unfortunately has an unpredictable course. The factors indicating a poor prognosis are the extent of hair loss at the presentation, long duration of the disease, and ophiasis pattern of hair loss. There are only a few randomized controlled studies conducted on recalcitrant AA. Recent research on immunology of hair follicle and recent developments in immunopathogenesis, together with the shared pathways of the disease with other autoimmune disorders, led investigators to focus on novel therapies that target specific immunological pathways. Herein, we will review shortly the current treatment options in recalcitrant alopecia areata based on recently published studies and then will focus on the recently developed broad-spectrum and targeted therapeutics.

show abstract

“…There are several case reports of AA developing in patients receiving treatment with the TNF-α blockers adalimumab and etanercept [99]. However biologic therapies targeting T cells may provide an alternative approach to the treatment of AA.…”

Section: Alopecia Areatamentioning

confidence: 99%

Biologics in Dermatology

Chandler

Bewley

2013

Pharmaceuticals

View full text Add to dashboard Cite

Skin and subcutaneous diseases affect millions of people worldwide, causing significant morbidity. Biologics are becoming increasingly useful for the treatment of many skin diseases, particularly as alternatives for patients who have failed to tolerate or respond to conventional systemic therapies. Biological therapies provide a targeted approach to treatment through interaction with specific components of the underlying immune and inflammatory disease processes. This review article examines the increasing evidence base for biologics in dermatology, including well-established treatments and novel agents.

show abstract

Pelade au cours d’un traitement par anti-TNF alpha : neuf cas

Cited by 29 publications

References 23 publications

Biologic: A Double Edged Sword - A Case of Etanercept Induced Alopecia Areata in a Patient with Psoriasis Vulgaris

Biologic: A Double Edged Sword - A Case of Etanercept Induced Alopecia Areata in a Patient with Psoriasis Vulgaris

New Modalities in the Treatment of Refractory Alopecia Areata

Biologics in Dermatology

Contact Info

Product

Resources

About